Imugene Share Price Up on Agreement with Merck and Pfizer (ASX:IMU)

The Imugene Ltd [ASX:IMU] share price is up 6% following a supply agreement update.

Imugene, the biotech stock, gained 600% over the last 12 months.

ASX IMU - Imugene Share Price ChartSource:

Let’s examine IMU’s deal with Pfizer and Merck further.

IMU inks deal with Merck and Pfizer

Imugene has signed a new clinical trial supply agreement with Merck KGaA [ETR:MRK] and Pfizer [NYSE:PFE].

The deal was signed to evaluate the safety and efficacy of Imugene’s HER-Vaxx immunotherapy product as it combines with avelumab in patients with HER-2 positive gastric cancer.

Avelumab, marketed as BAVENCIO, is co-developed and co-commercialised by Merck and Pfizer.

Under the deal, IMU will receive avelumab for a Phase 2 clinical study in HER-2 positive gastric or gastroesophageal junction adenocarcinomas (neoHERIZON).

As Imugene explains:

neoHERIZON is an open-label, multi-center, randomized, Phase 2 clinical trial designed to assess the safety and efficacy of perioperative HER-Vaxx combined with chemotherapy with or without avelumab compared to chemotherapy alone in patients with HER-2 positive gastric or gastroesophageal junction adenocarcinomas. The study’s primary endpoint is pathologic complete response. Secondary endpoints include safety and biomarker evaluation.’

What are the terms of the deal?

Imugene will act as the sponsor of the study — funding the clinical trials from ‘existing budgets and resources.

Merck KGaA and Pfizer will provide the avelumab for the duration of the study.

For reference, in its latest quarterly, IMU reported having $112 million in cash and cash equivalents, having spent $5.4 million on research and development in the September quarter.

How to Limit Your Risks While Trading Volatile Stocks. Learn more.

IMU share price outlook

Imugene said moving the HER-Vaxx into earlier gastric cancer in combination with chemotherapy ‘may improve treatment outcomes for patients with this difficult to treat cancer.

Leslie Chong, Managing Director and Chief Executive Officer of Imugene, commented:

Imugene is excited to announce this collaboration with Merck KGaA, Darmstadt, Germany and Pfizer. HER-Vaxx has shown a tolerable safety profile and encouraging efficacy in patients with metastatic HER-2 positive gastric cancer, and we are looking forward to evaluating HER-Vaxx with avelumab in the perioperative clinical setting. Working together, we’re committed to finding ways to address the unmet needs of patients living with cancer.’

Breakthroughs in treating cancers previously resistant to treatment make biotech stocks exciting plays for many investors.

But the same excitement over a potential treatment breakthrough also reveals just how rare those breakthroughs are.

Biotech stocks come with lots of potential…and plenty of risk.

That said, there are plenty of unique, high-potential opportunities to consider right now, particularly for those interested in getting into smaller ambitious companies.

These sorts of companies might be high risk, but if they achieve the level of success they’re shooting for, large gains could be for the taking.

Our leading small-cap stock market analyst Murray Dawes has found seven stocks on the ASX today he believes fit this description.

I recommend checking out Murray’s thoughts on these stocks.

There are some compelling ideas in there.


Kiryll Prakapenka,
For Money Morning

PS: Our publication Money Morning is a fantastic place to start on your investment journey. We talk about the big trends driving the most innovative stocks on the ASX. Learn all about it here

Kiryll Prakapenka is a research analyst focusing on investigating the biggest trends in investments. Kiryll brings sound analytical skills to his work, courtesy of his Philosophy degree from the University of Melbourne. A student of legendary investors and their strategies, Kiryll likes to synthesise macroeconomic narratives with a keen understanding of the fundamentals behind companies..

Money Morning Australia